Coeptis Therapeutics Amends Merger Proxy to Correct Post-Merger Shareholder Ownership Details
COEP has more than doubled off its 52-week low of $6.26.
Summary
Coeptis Therapeutics Holdings, Inc. filed a supplement to its January 5, 2026 proxy statement, correcting typographical errors in the post-merger principal stockholder table for the reverse merger with Z Squared Inc.
Key Events · Corporate Governance and Compliance · COEP
-
Corrects Post-Merger Ownership Data
The filing amends the proxy statement dated January 5, 2026, to correct typographical errors in the "Principal Stockholders of Proposed Combined Company" table.
-
Clarifies Major Shareholder Stakes
The correction impacts the reported beneficial ownership percentages, including BSG Series CM at 73.37% and the executive officers and directors as a group at 2.79% post-merger.
-
Relates to Prior Reverse Merger Disclosure
This supplement follows the 424B3 filing on January 5, 2026, which announced the reverse merger with Z Squared Inc., a cryptocurrency mining firm.
Analysis · COEP · Crypto Assets
This DEFA14A filing is important as it provides corrected and clarified information regarding the post-merger ownership structure of Coeptis Therapeutics Holdings, Inc. following its reverse merger with Z Squared Inc. While described as "typographical errors," changes to the principal stockholder table, especially for a combined entity, are material for investors assessing control and potential dilution. The correction ensures accurate disclosure of who will hold significant stakes in the company after the merger, which is a critical detail for shareholders voting on the transaction.
At the time of this filing, COEP was trading at $13.61 on NASDAQ in the Crypto Assets sector, with a market capitalization of approximately $77.3M. The 52-week trading range was $6.26 to $21.41. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.